William G Powderly

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Sorting through confusing messages: the art of HAART
    William G Powderly
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
    J Acquir Immune Defic Syndr 31:S3-9; discussion S24-5. 2002
  2. ncbi request reprint Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits
    William G Powderly
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Infect Dis 38:S109-13. 2004
  3. ncbi request reprint Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection
    Pablo Tebas
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    AIDS Res Hum Retroviruses 20:589-94. 2004
  4. ncbi request reprint Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy
    Marisa T Gerber
    Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA
    Clin Infect Dis 39:419-25. 2004
  5. ncbi request reprint Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons
    Edgar Turner Overton
    Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 41:1045-8. 2005
  6. pmc Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART
    W Todd Cade
    Department of Medicine, Washington University School of Medicine, 4444 Forest Park Blvd, St Louis, MO 63108 2212, USA
    Am J Physiol Endocrinol Metab 292:E812-9. 2007
  7. ncbi request reprint Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis
    Somnuek Sungkanuparph
    Washington University School of Medicine, St Louis, MO, USA
    Clin Infect Dis 41:1326-32. 2005
  8. pmc Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy
    Kristin E Mondy
    Washington University School of Medicine, St Louis, MO, USA
    AIDS 22:849-56. 2008
  9. pmc Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms
    Brian R Wood
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    AIDS 27:967-72. 2013
  10. pmc Whole-body proteolysis rate is elevated in HIV-associated insulin resistance
    Dominic N Reeds
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Diabetes 55:2849-55. 2006

Detail Information

Publications38

  1. ncbi request reprint Sorting through confusing messages: the art of HAART
    William G Powderly
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
    J Acquir Immune Defic Syndr 31:S3-9; discussion S24-5. 2002
  2. ncbi request reprint Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits
    William G Powderly
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Infect Dis 38:S109-13. 2004
    ..We need more research in this area, especially with regard to mechanisms, risks, and management--for specific drugs and regimens--to ensure that our patients receive the benefits of antiretroviral therapy in the safest manner possible...
  3. ncbi request reprint Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection
    Pablo Tebas
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    AIDS Res Hum Retroviruses 20:589-94. 2004
    ..Our study supports a pathogenic role for PIs in the development of hypertriglyceridemia and insulin resistance, but a more limited role in the fat redistribution syndrome...
  4. ncbi request reprint Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy
    Marisa T Gerber
    Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA
    Clin Infect Dis 39:419-25. 2004
    ..Extended release (ER)-niacin therapy, which has been associated with reduced glucose tolerance in human immunodeficiency virus (HIV)-seronegative individuals, has not been evaluated in the HIV-infected population...
  5. ncbi request reprint Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons
    Edgar Turner Overton
    Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 41:1045-8. 2005
    ..5%) developed a protective antibody response. In a logistic regression model, only a plasma HIV RNA level of <400 copies/mL at the time of vaccination was associated with a protective antibody response (P=.003)...
  6. pmc Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART
    W Todd Cade
    Department of Medicine, Washington University School of Medicine, 4444 Forest Park Blvd, St Louis, MO 63108 2212, USA
    Am J Physiol Endocrinol Metab 292:E812-9. 2007
    ..Regional differences in adipose tissue lipolysis during rest and moderate exercise may be important in HIV and warrant further study...
  7. ncbi request reprint Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis
    Somnuek Sungkanuparph
    Washington University School of Medicine, St Louis, MO, USA
    Clin Infect Dis 41:1326-32. 2005
    ..Limited data are available for patients treated with nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based regimens...
  8. pmc Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy
    Kristin E Mondy
    Washington University School of Medicine, St Louis, MO, USA
    AIDS 22:849-56. 2008
    ..To address this issue, we assessed multiple metabolic and clinical predictors of endothelial function and carotid intima-media thickness in HIV-infected subjects and compared results with HIV-negative controls...
  9. pmc Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms
    Brian R Wood
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    AIDS 27:967-72. 2013
    ..The objective of this study was to define the test characteristics of plasma beta-glucan for diagnosis of Pneumocystis jirovecii pneumonia (PCP) in AIDS patients with respiratory symptoms...
  10. pmc Whole-body proteolysis rate is elevated in HIV-associated insulin resistance
    Dominic N Reeds
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Diabetes 55:2849-55. 2006
    ..Increased proteolysis may provide amino acids for gluconeogenesis, exacerbating hyperglycemia in HIV...
  11. pmc Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy
    Juan Chaparro
    Departments of Medicine and Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Metabolism 54:561-7. 2005
    ..Prospective longitudinal studies of thigh fat adipose tissue gene expression could provide further insights on the pathogenesis of metabolic complications associated with PI-based HAART...
  12. ncbi request reprint Limitations of current HIV therapies: opportunities for improvement
    William G Powderly
    Washington University School of Medicine, St Louis, Missouri, USA
    J Acquir Immune Defic Syndr 33:S7-12; quiz S13, 15-6. 2003
  13. pmc Reducing plasma HIV RNA improves muscle amino acid metabolism
    Kevin E Yarasheski
    Department of Internal Medicine, Division of Metabolism, Endocrinology and Lipid Research, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Physiol Endocrinol Metab 288:E278-84. 2005
    ....
  14. ncbi request reprint Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection
    Kristin Mondy
    Washington University School of Medicine, Division of Infectious Diseases, St Louis, MO, USA
    J Acquir Immune Defic Syndr 38:426-31. 2005
    ..We conducted a 48-week prospective, randomized, open-label study to evaluate the effects of alendronate, vitamin D, and calcium supplementation on bone mineral density (BMD) in patients with HIV infection...
  15. ncbi request reprint Hepatic steatosis and HIV infection
    Maria Ristig
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, USA
    AIDS Patient Care STDS 19:356-65. 2005
    ..Further work is also needed to elucidate the pathogenesis and to evaluate the therapeutic effect of treating comorbidities and avoiding certain antiretroviral drugs...
  16. pmc GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals
    Edgar T Overton
    Washington University, St Louis, MO, USA
    Open Virol J 5:109-13. 2011
    ..Data regarding booster HBV vaccine for persons with low HBV surface antibody (sAb) titers after vaccination in this immunocompromised population is lacking...
  17. ncbi request reprint Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies
    Pablo Tebas
    Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Infect Dis 186:851-4. 2002
    ..In a multiple regression analysis model, the increase of CD4(+) T cells while receiving therapy and age were independently associated with the rate of CD4(+) T cell loss...
  18. ncbi request reprint Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
    Daniel R Kuritzkes
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
    J Infect Dis 189:286-91. 2004
    ..We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects...
  19. ncbi request reprint Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic
    Jessica R Grubb
    Washington University School of Medicine, St Louis, Missouri, USA
    AIDS 20:2115-6. 2006
    ..There did not seem to be a significant difference in primary resistance patterns between different modes of HIV transmission (heterosexual versus men who have sex with men), gender or between white and African-American individuals...
  20. ncbi request reprint Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia
    Kevin E Yarasheski
    Division of Endocrinology, Metabolism and Lipid Research, Washington University Medical School, 660 South Euclid Avenue, Box 8127, St Louis, MO 63110, USA
    Am J Physiol Endocrinol Metab 285:E899-905. 2003
    ..g., central adiposity and hyperinsulinemia) and mediated only partially by factors that influence triglyceride clearance (e.g., lipase activity)...
  21. ncbi request reprint Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed
    Maria B Ristig
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Infect Dis 186:1844-7. 2002
    ..There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals...
  22. ncbi request reprint Opportunities to improve clinical care in HIV disease: designing an effective antiretroviral drug regimen for your patient. Introduction
    William G Powderly
    Washington University School of Medicine, St Louis, Missouri, USA
    J Acquir Immune Defic Syndr 33:S5-6. 2003
  23. ncbi request reprint A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40
    Mitchell Goldman
    Indiana University School of Medicine, Division of Infectious Diseases, Wishard Memorial Hospital, Indianapolis, IN 46202, USA
    Clin Infect Dis 41:1473-80. 2005
    ..However, concerns exist with regard to the use of fluconazole prophylaxis and the risk of development of fluconazole treatment-refractory infections...
  24. ncbi request reprint Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals
    Kristin Mondy
    Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
    Clin Infect Dis 36:482-90. 2003
    ..Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors...
  25. ncbi request reprint Switching effective antiretroviral therapy: a review
    Henning Drechsler
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Infect Dis 35:1219-30. 2002
    ..Larger, controlled, long-term studies and a more standardized approach to definition of metabolic and morphological abnormalities are needed...
  26. pmc Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 53:197-202. 2011
    ..See the editorial commentary by Morris and Masur, on pages 203-204.)..
  27. pmc The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling
    Michael W H Wang
    Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    J Clin Invest 114:206-13. 2004
    ..Thus, ritonavir may represent a bone-sparing PI capable of preventing development of osteopenia in patients currently on HAART...
  28. ncbi request reprint Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine
    Erik J Uhlmann
    Department of Pathology, Box 8118, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Virol 31:198-203. 2004
    ..Cross resistance is common among the non-nucleoside reverse transcriptase inhibitors (NNRTIs). G190A appears in 5-15% of the patients treated with nevirapine or efavirenz who develop clinical resistance...
  29. doi request reprint Antiretroviral therapy in primary HIV infection
    William G Powderly
    Division of Infectious Diseases, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Comp Eff Res 2:227-9. 2013
    ....
  30. ncbi request reprint Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
    Morris Schambelan
    University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
    J Acquir Immune Defic Syndr 31:257-75. 2002
    ..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
  31. ncbi request reprint Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
    Kathleen Squires
    Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 36:1011-9. 2004
    ..Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia...
  32. pmc Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
    ..The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs...
  33. pmc Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk
    Pablo Tebas
    University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 3:e2021. 2008
    ..Our goal was to evaluate fasting metabolic changes associated with interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk...
  34. pmc Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study
    Carl Grunfeld
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 46:283-90. 2007
    ..Thus, VAT and upper trunk SAT are independently associated with insulin resistance in controls and in HIV-infected persons...
  35. ncbi request reprint Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy
    Edgar T Overton
    AIDS 19:1439. 2005
  36. ncbi request reprint Centers for Disease Control and Prevention revised guidelines for human immunodeficiency virus (HIV) counseling, testing, and referral: targeting HIV specialists
    William G Powderly
    Clin Infect Dis 37:813-9. 2003
  37. ncbi request reprint HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts
    Andrea P Malizia
    General Clinical Research Unit, Mater Misericordiae University Hospital, School of Medicine and Medical Sciences, University College Dublin, 44 Eccles Street, Dublin 7, Ireland
    AIDS Res Hum Retroviruses 23:243-50. 2007
    ..Our data suggest a link between reduced osteoblastic phenotype and a group of 21 altered genes following NFV and IDV treatment, and also suggest TIMP-3 may be involved in the PI-induced inhibition of osteoblast function...
  38. ncbi request reprint Developing a human immunodeficiency virus/acquired immunodeficiency syndrome therapeutic research agenda for resource-limited countries: a consensus statement
    Sten H Vermund
    University of Alabama at Birmingham, Birmingham, AL 35294 2170, USA
    Clin Infect Dis 37:S4-12. 2003
    ..To achieve sustainable approaches to HIV/acquired immunodeficiency syndrome care, research relevant to resource-limited settings must involve local researchers and community representatives to promote development of local capacity...